For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Optimal Timing and Sequence of Immunotherapy When Combined with Stereotactic Radiosurgery in the Treatment of Brain Metastases.

TitleOptimal Timing and Sequence of Immunotherapy When Combined with Stereotactic Radiosurgery in the Treatment of Brain Metastases.
Publication TypeJournal Article
Year of Publication2019
AuthorsEljalby M, Pannullo SC, Schwartz TH, Parashar B, A Wernicke G
JournalWorld Neurosurg
Volume127
Pagination397-404
Date Published2019 Jul
ISSN1878-8769
KeywordsBrain Neoplasms, Clinical Trials as Topic, Combined Modality Therapy, Humans, Immunotherapy, Radiosurgery, Retrospective Studies, Time Factors, Treatment Outcome
Abstract

Checkpoint immunotherapy (CIT) is an emerging and exciting treatment modality for the treatment of cancer. Much excitement has ensued in the potential of CIT to revolutionize the treatment and prognosis of brain metastases. The combination of stereotactic radiosurgery (SRS) and CIT has also been studied and showed promise compared with either treatment modality alone. However, several questions have arisen, in particular, the timing at which SRS and CIT should be administered relative to each other. We reviewed the reported data and attempted to offer a potential answer to this question.

DOI10.1016/j.wneu.2019.04.093
Alternate JournalWorld Neurosurg
PubMed ID31004856